{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:42:08Z","timestamp":1792698128396,"version":"4.5.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background and aim<\/jats:title>\n                    <jats:p>Considering the increasing prevalence of non-alcoholic steatohepatitis (NASH) and treatment gaps, this study aimed to evaluate the effect of probiotic supplementation on liver function markers, nutritional status, and clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This double-blind, randomized clinical trial (\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      ID: NCT0346782) included adult outpatients with biopsy-proven NASH. The intervention consisted of 24\u2009weeks of supplementation with the probiotic mix\n                      <jats:italic>Lactobacillus acidophilus<\/jats:italic>\n                      (1\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \u2009CFU)\u2009+\u2009\n                      <jats:italic>Lactobacillus rhamnosus<\/jats:italic>\n                      (1\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \u2009CFU)\u2009+\u2009\n                      <jats:italic>Lactobacillus paracasei<\/jats:italic>\n                      (1\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \u2009CFU)\u2009+\u2009\n                      <jats:italic>Bifidobacterium lactis<\/jats:italic>\n                      (1\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \u2009CFU), or placebo, twice a day. The following parameters were evaluated: demographic and clinical data, transient elastography (FibroScan), liver enzymes, NAFLD\n                      <jats:italic>fibrosis score<\/jats:italic>\n                      , fatty liver index, laboratory assessment, serum concentration of toll-like receptor-4 (sTLR-4) and cytokeratin 18 (CK-18), anthropometric data, dietary intake, and physical activity. Regarding data analysis, the comparison between the groups was based on the delta of the difference of each variable analyzed (value at the end of treatment minus the baseline value) using the\n                      <jats:italic>t<\/jats:italic>\n                      -test for independent samples or the Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      -test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-four patients with NASH completed the trial (51.4\u2009\u00b1\u200911.6\u2009years). At baseline, 87% of participants had a mild liver fibrosis degree on biopsy, normal values of liver enzymes, transient elastography values consistent with grade 1 fibrosis in both groups, increased waist circumference (WC), a BMI of 30.97\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , and 76% presented with metabolic syndrome (MetS). After the intervention, no differences were observed between the probiotic and placebo groups in terms of MetS, WC, BMI scores, or liver enzyme levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05 for all). The elastography values remained consistent with grade 1 fibrosis in both groups. Although CK-18 was reduced in both groups, a larger effect size was noted in the probiotic group (\n                      <jats:italic>D<\/jats:italic>\n                      \u2009=\u20091.336). sTLR-4 was also reduced in both groups, with no difference between groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.885).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intervention with probiotics in the early stages of NASH demonstrated no significant change in hepatic and clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier NCT0346782.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2024.1362694","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T01:08:24Z","timestamp":1711501704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Probiotic supplementation for 24\u2009weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial"],"prefix":"10.3389","volume":"11","author":[{"given":"Amanda Souza","family":"Silva-Sperb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Abadie","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha Thifani Alrutz","family":"Barcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Concheski","family":"de Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisse","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Truccolo","family":"Michalczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Thadeu Schmidt","family":"Cerski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Uribe-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themis Reverbel","family":"da Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio Reis","family":"\u00c1lvares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca","family":"Dall\u2019Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7150\/ijbs.56214","article-title":"Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: recent updates","volume":"17","author":"Khan","year":"2021","journal-title":"Int J Biol Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10096-019-03746-1","article-title":"Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies","volume":"39","author":"Ebrahimzadeh Leylabadlo","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.livres.2017.11.005","article-title":"Gut microbiota, fatty liver disease, and hepatocellular carcinoma","volume":"2","author":"Chu","year":"2018","journal-title":"Liver Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/diseases7010027","article-title":"The therapeutic implications of the gut microbiome and probiotics in patients with NAFLD","volume":"7","author":"Perumpail","year":"2019","journal-title":"Diseases"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/jcm8081089","article-title":"Gut microbiota and risk of persistent nonalcoholic fatty liver diseases","volume":"56","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3390\/nu11112642","article-title":"The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies","volume":"11","author":"Meroni","year":"2019","journal-title":"Nutrients"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/nutrit\/nuz022","article-title":"Dietary interventions, intestinal microenvironment, and obesity: a systematic review","volume":"77","author":"Santos","year":"2019","journal-title":"Nutr Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/jgh.16256","article-title":"Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"38","author":"Rong","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e32734","DOI":"10.1097\/MD.0000000000032734","article-title":"Efficacy of probiotics on nonalcoholic fatty liver disease: a meta-analysis","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/9729107","article-title":"Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"2017","author":"He","year":"2017","journal-title":"Biomed Res Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-gomez","year":"2018","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.aohep.2020.08.066","article-title":"Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population","volume":"19","author":"Zambrano-huailla","year":"2020","journal-title":"Ann Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/s13063-019-3679-7","article-title":"Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER trial protocol","volume":"20","author":"Silva-Sperb","year":"2019","journal-title":"Trials"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.aohep.2022.100769","article-title":"Oral 24-week probiotics supplementation did not decrease cardiovascular risk makers in patientes with biopsy proven NASH: a double-blind placebo-controlled randomized study","volume":"28","author":"Barcelos","year":"2023","journal-title":"Ann Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World gastroenterology organisation global guidelines nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","author":"DR","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13098-018-0347-0","article-title":"Optimal cut-off points for waist circumference in the definition of metabolic syndrome in Brazilian adults: baseline analyses of the Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"10","author":"Cardinal","year":"2018","journal-title":"Diabetol Metab Syndr"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatologty"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Bauman","year":"2000","journal-title":"Med Sci Sport Exerc"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/\/0033-2909.112.1.155","article-title":"A power primier","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9181368","article-title":"Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach","volume":"2020","author":"Grgurevic","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.cgh.2014.08.005","article-title":"Trials and tribulations in drug development for nonalcoholic steatohepatitis","volume":"12","author":"Sanyal","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/liv.14355","article-title":"Current management of non-alcoholic steatohepatitis","volume":"40","author":"Muthiah","year":"2020","journal-title":"Liver Int"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.19043.1","article-title":"Probiotics and prebiotics in clinical tests: an update","volume":"8","author":"Br\u00fcssow","year":"2019","journal-title":"F1000Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1756284819878046","DOI":"10.1177\/1756284819878046","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Tang","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"844242","DOI":"10.3389\/fnut.2022.844242","article-title":"Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver disease: an umbrella of systematic review and meta-analysis","volume":"9","author":"Musazadeh","year":"2022","journal-title":"Front Nutr"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/apt.15416","article-title":"Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease","volume":"50","author":"Koopman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MOG.0000000000000039","article-title":"The gut microbiota and the metabolic health of the host","volume":"30","author":"Joyce","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J Gastrointest Liver Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of Histologic Disease Activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/MEG.0000000000001371","article-title":"The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease\u2014a systematic review and meta-analysis","volume":"31","author":"Khan","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CM9.0000000000002603","article-title":"Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin Med J"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4291\/wjgp.v6.i4.99","article-title":"Starring role of toll-like receptor-4 activation in the gut-liver axis","volume":"6","author":"Carotti","year":"2015","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/met.2013.0120","article-title":"TLR4 gene polymorphism in patients with nonalcoholic","volume":"12","author":"Kiziltas","year":"2014","journal-title":"Metab Syndr Relat Disord"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00203-023-03752-0","article-title":"Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets","volume":"206","author":"Gruzdev","year":"2024","journal-title":"Arch Microbiol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.bpj.2015.06.048","article-title":"A structural view of negative regulation of the toll-like receptor-mediated inflammatory pathway","volume":"109","author":"Guven-Maiorov","year":"2015","journal-title":"Biophys J"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"36783","DOI":"10.1038\/srep36783","article-title":"Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"6","author":"Dong","year":"2016","journal-title":"Sci Rep"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"2","author":"Wong","year":"2013","journal-title":"Ann Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5005\/jp-journals-10018-1226","article-title":"Probiotic therapy in patients with nonalcoholic steatohepatitis in Zagazig University Hospitals","volume":"7","author":"Monem","year":"2017","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"ref51","first-page":"1090","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of Lactobacillus rhamnosus strain GG in pediatric","volume":"52","author":"Vajro","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1362694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T01:08:28Z","timestamp":1711501708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1362694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":56,"alternative-id":["10.3389\/fnut.2024.1362694"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2024.1362694","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"article-number":"1362694"}}